Compare NKX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKX | PHAR |
|---|---|---|
| Founded | 2002 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.3M | 793.4M |
| IPO Year | 2002 | 2020 |
| Metric | NKX | PHAR |
|---|---|---|
| Price | $11.46 | $10.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.33 |
| AVG Volume (30 Days) | ★ 162.5K | 15.3K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.60 | $9.62 |
| 52 Week High | $13.20 | $21.34 |
| Indicator | NKX | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 19.53 | 41.13 |
| Support Level | N/A | $9.62 |
| Resistance Level | $12.49 | $13.51 |
| Average True Range (ATR) | 0.11 | 0.36 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 10.87 | 19.09 |
Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.